Bacterial lipopolysaccharides (LPS) released from gram negative bacteria are toxic and have been shown to induce dyslipidemia, diabetes and neurodegenerative diseases. LPS has been linked to chronic inflammation and neuron death with relevance to various neurodegenerative diseases. In the developing world plasma LPS has been shown to be elevated and associated with the various chronic diseases. The role of specific drugs that lower plasma LPS levels is of major interest to reduce inflammation and LPS toxicity to various tissues and organs in the developing world. The role of cholesterol lowering drugs have been assessed with relevance to reduce LPS inflammation but the reduction in plasma LPS requires further evaluation.
RELEVANT REFERENCES:
A. J. McFarland, A. K. Davey, and S. Anoopkumar-Dukie. Statins Reduce Lipopolysaccharide-Induced Cytokine and Inflammatory Mediator Release in an In Vitro Model of Microglial-Like Cells. Mediators Inflamm. 2017; 2017: 2582745.
B. Wu, S., Duan, S., Zhao, S. et al. Atorvastatin reduces lipopolysaccharide-induced expression of cyclooxygenase-2 in human pulmonary epithelial cells. Respir Res 6, 27 (2005).
C. Bacterial Lipopolysaccharides and Neuron Toxicity in Neurodegenerative Diseases. Neurology Research and Surgery. 2018; 1(1): 1-3.
D. Overnutrition Determines LPS Regulation of Mycotoxin Induced Neurotoxicity in Neurodegenerative Diseases. Int J Mol Sci.2015; 16(12): 29554–29573.
E. LPS Regulates Apolipoprotein E and Aβ Interactions with Effects on Acute Phase Proteins and Amyloidosis. Advances in Aging Research 03/2015; 4(2):69-77.
- Badges
- Science topic
- Similar topics
- Biological Science
- Biochemistry
- Enzymology
- Enzymes